Jul 3 |
MRK
|
Merck: Among The Best Health Care GARP Plays Today |
Jul 2 |
MRK
|
mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment |
Jul 2 |
MRK
|
N-Power Medicine partners with MSD to expand access to oncology clinical trials |
Jul 1 |
MRK
|
5 Biggest Winners, 5 Biggest Losers From Dow Jones Industrial Average In First Half 2024 |
Jul 1 |
MRK
|
What's Going On With Merck Stock On Monday? |
Jul 1 |
MRK
|
Orion to hand over exclusive rights to MSD for prostate cancer therapy |
Jul 1 |
MRK
|
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer |
Jul 1 |
MRK
|
Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30 |
Jul 1 |
MRK
|
10 clinical trials to watch in the second half of 2024 |
Jun 30 |
MRK
|
Questor: This ‘wonder drug’ firm is being backed by top fund managers |
Jun 29 |
MRK
|
How Do These 3 Healthcare Dividend Stocks Deliver Reliable Income And Growth? |
Jun 28 |
MRK
|
How Medicare drug price negotiations could hit pharma stocks |
Jun 28 |
MRK
|
Merck lung disease therapy Winrevair endorsed in EU |
Jun 28 |
MRK
|
What's Going On With Merck Stock On Friday? |
Jun 28 |
MRK
|
Merck’s pneumococcal vaccine gets CDC panel backing |
Jun 28 |
MRK
|
Merck Capvaxive pneumonia vaccine recommended by CDC advisors |
Jun 28 |
MRK
|
Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote |
Jun 28 |
MRK
|
Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH) |
Jun 28 |
MRK
|
CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults |
Jun 27 |
MRK
|
Dow Jones Powerhouse Merck Dives On Surprise FDA Rejection |